JPRN-jRCTb060220083招募中1 期
Therapy for prevention of renal failure in CKD patients using autologous adipose tissue-derived mesenchymal stem cells cultured in serum-free medium - PREMISE
akashima Ayumu0 个研究点目标入组 10 人开始时间: 2023年1月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 < 80age old（—）
- 性别
- All
入选标准
- •1) Patient with written informed consent.
- •2) Patient with Performance Status (PS) 0 or 1.
- •3) Both genders, 18 to 80 years old.
- •4) Chronic kidney disease patients due to diabetic kidney disease, IgA nephropathy, or nephrosclerosis.
- •5) Patients with eGFR 30-60 mL/min/1.73 m2 and proteinuria (more than 0.15 g/gCre) for 3 months or more.
排除标准
- •1) Patients with renal diseases other than diabetic kidney disease, IgA nephropathy, nephrosclerosis, or patients with primary and secondary nephrotic syndrome.
- •2) Patients with a history of renal transplantation or scheduled within 3 years.
- •3) Patients with active infectious diseases requiring intravenous administration of antimicrobial agents, antiviral drugs, and antifungal drugs.
- •4) Patients with positive for hepatitis B virus, hepatitis C virus, human Immunodeficiency virus (HIV), human T-cell leukemia virus 1 (HTLV-1) or syphilis.
- •5) Patients receiving corticosteroids, immunosuppressants, anticoagulants (warfarin) and antiplatelet drugs (including patients who received these within 3 months).
- •6) Diabetics not well controlled.
- •7) Patients with malignant neoplasm or history of malignant neoplasm within 5 years, or judged possibility of malignant tumor.
- •8) Patients with mental illness or drug dependence.
- •9) Patients with serious complications such as heart disease, respiratory disease and liver disease.
- •10) Patients with history of severe hypersensitivity or anaphylactic reaction.
- •11) Patients with or have a history of Allergies to penicillin antibiotics or aminoglycoside antibiotics.
- •12) Patients with bleeding, easy bleeding or abnormality in the blood coagulation system.
- •13) Patients with history of hypersensitivity to components of heparin preparations, history of heparin-induced thrombocytopenia.
- •14) Patients who have participated in clinical studies with intervention within 6 month, or who are participating in other clinical studies.
- •15) Patients who have received other cell therapies.
- •16) During pregnancy, lactation, may be pregnant or both men and women who do not agree to give birth control under the guidance of the investigator or investigator during the study period.
- •17) Patients judged by the doctor to be inappropriate for participation.
研究者
相似试验
已完成
不适用
The prevention of progression in CKD of medication adherence to AST-120 in patients with non-dialysis chronic kidney disease (CKD) and significance of measurement indoxyl sulfate as an indicator of medication adherencenon-dialysis chronic kidney diseaseJPRN-UMIN000023724Jichi Medical University100
招募中
不适用
Reducing renal function deterioration by means of increasing medication adherence, improving immunosuppressive drug exposure and supporting a healthy lifestyle - an implementation studyRenal transplantationImmunosuppressantsMedication adherencee-HealthPatient participationNL-OMON20914eiden University Medical Center, Leiden, The Netherlands100
已完成
不适用
Reducing renal function deterioration by means of increasing medication adherence, improving immunosuppressive drug exposure and supporting a healthy lifestyle - an implementation study.NL-OMON50600eids Universitair Medisch Centrum100
已完成
不适用
Prevention of acute renal failure, molecular mechanism of dietary preconditioning in human.N17Acute renal failureDRKS00007704niversität zu Köln24
已完成
不适用
PRevention of End stage kidney disease by Darbepoetin Alfa In CKD patients with non-diabeTic kidney disease.JPRN-UMIN000006616PREDICT steering committee440